ESMO 2017: Combination immunotherapy with nivolumab or nivolumab plus ipilimumab in second- or third-line extends mesothelioma survival to 15 months

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Immunotherapy with nivolumab or nivolumab and ipilimumab as second- or third-line treatment extends overall survival in patients with malignant pleural mesothelioma according to MAPS2 trial.

Why this matters

  • There is no approved second-line treatment for malignant pleural m...